{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:32:08Z","timestamp":1788388328900,"version":"build-2803163510"},"reference-count":14,"publisher":"Elsevier BV","issue":"40","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.vaccine.2020.07.013","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T17:59:40Z","timestamp":1594403980000},"page":"6194-6198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Planning for COVID-19 vaccines safety surveillance"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1150-5691","authenticated-orcid":false,"given":"Sonali","family":"Kochhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Salmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.07.013_b0005","unstructured":"CEPI. Creating a world in which epidemics are no longer a threat to humanity. Accessed on Mar 19, 2020 at https:\/\/cepi.net\/about\/whyweexist\/."},{"key":"10.1016\/j.vaccine.2020.07.013_b0010","unstructured":"CEPI 2019-nCoV vaccine. Accessed on April 7, 2020 at https:\/\/cepi.net\/?s=2019-nCoV."},{"key":"10.1016\/j.vaccine.2020.07.013_b0015","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","article-title":"New Vaccine Technologies to Combat Outbreak Situations","volume":"9","author":"Rauch","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2020.07.013_b0020","unstructured":"COVID-19 vaccine development pipeline. 29 June 2020, accessed on June 29, 2020 at https:\/\/vac-lshtm.shinyapps.io\/ncov_vaccine_landscape\/."},{"key":"10.1016\/j.vaccine.2020.07.013_b0025","unstructured":"WHO. Draft landscape of COVID-19 candidate vaccines \u2013 29 June 2020. Accessed on June 29, 2020 at https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines."},{"issue":"3","key":"10.1016\/j.vaccine.2020.07.013_b0030","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV \u2014 a target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat Rev Microbiol"},{"issue":"31","key":"10.1016\/j.vaccine.2020.07.013_b0035","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1016\/j.vaccine.2020.05.064","article-title":"Consensus summary report for CEPI\/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines","volume":"38","author":"Lambert","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.07.013_b9000","unstructured":"Brighton Collaboration. Accessed on 29 June 2020 at https:\/\/brightoncollaboration.us\/category\/news\/covid\/."},{"key":"10.1016\/j.vaccine.2020.07.013_b9005","doi-asserted-by":"crossref","unstructured":"Chen RT, Kochhar S, Condit RC The Brighton Collaboration standardized templates for collection of key information for benefit-risk assessment of vaccines by technology (BRAVATO; formerly V3SWG). Vaccine. 2020;38:6184\u20139.","DOI":"10.1016\/j.vaccine.2020.07.028"},{"key":"#cr-split#-10.1016\/j.vaccine.2020.07.013_b9010.1","unstructured":"World Health Organization. Global Advisory Committee on Vaccine Safety, 27-28 May 2020: Conclusion and recommendations. Wkly Epidem Rec 2020"},{"key":"#cr-split#-10.1016\/j.vaccine.2020.07.013_b9010.2","unstructured":"95:336. Accessed on July 22, 2020 at https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/333136\/WER9528-eng-fre.pdf?ua=1."},{"key":"10.1016\/j.vaccine.2020.07.013_b0040","unstructured":"Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). Accessed on June 24, 2020 at https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-guidance-management-patients.html."},{"issue":"Supplement","key":"10.1016\/j.vaccine.2020.07.013_b0045","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1542\/peds.2010-1722L","article-title":"Immunization-Safety Monitoring Systems for the 2009 H1N1 Monovalent Influenza Vaccination Program","volume":"127","author":"Salmon","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2020.07.013_b0050","unstructured":"World Health Organization. Global Vaccine Safety Blueprint 2.0 (GVSB2.0). Draft 1 for public consultation. Accessed on Mar 17, 2020 at https:\/\/www.who.int\/vaccine_safety\/Draft_GVSB2.0_20190929.pdf?ua=1."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20309130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20309130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:46:39Z","timestamp":1759401999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20309130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":14,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0264410X20309130"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.07.013","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Planning for COVID-19 vaccines safety surveillance","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}